title: Immunohistochemical Localization of Wild-type EGFR, E746-A750 Frame Deletion in Exon 19, and L858R Point Mutation in Exon 21 in Triple-negative Breast Cancer.
abstract: OBJECTIVE
  This study evaluated wild-type EGFR, E746-A750 frame deletion in exon 19, and L858R point mutation in exon 21 by immunohistochemistry in patients with triple-negative breast cancer (TNBC).
  
  
  METHODS
  A retrospective study included 99 untreated early-stage and advanced-stage TNBC patients. Immunohistochemical localization of wild-type EGFR, EGFR E746-A750 deletion in exon 19, and EGFR L858R mutation in exon 21 was performed on formalin-fixed paraffin-embedded tissue blocks using mutation-specific primary antibodies.
  
  
  RESULTS
  EGFR protein expression was noted in 27% (27/99) of patients with 2+ or 3+ staining intensity in 7% (7/99) of patients. Significant correlation of EGFR protein expression with subgroups of clinicopathologic parameters was not found. In univariate and multivariate survival analysis, high EGFR expression (2+ or 3+) emerged as a significant prognostic factor for disease-free survival. With respect to mutation status, exon 19 deletion was observed in 3% (3/99) of patients. One patient with exon 19 deletion having high EGFR protein (2+) expression developed lung metastasis, whereas the other 2 patients with exon 19 deletion had low EGFR protein (1+) expression and remained disease free during the study period.
  
  
  CONCLUSIONS
  EGFR protein overexpression was observed in one fourth of TNBCs with very low incidence of EGFR-activating mutations in patients of western India.
authors: *Immunohistochemistry & Flow Cytometry Division †Department of Medical Oncology, The Gujarat Cancer and Research Institute, NCH Compound, Asarwa, Ahmedabad, India.
authors: Hemangini H
authors: HH
authors: Vora
authors: Nupur A
authors: NA
authors: Patel
authors: Prushin M
authors: PM
authors: Thakore
authors: Shilin N
authors: SN
authors: Shukla
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D001483:Base Sequence; D004252:DNA Mutational Analysis; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005091:Exons; D005260:Female; D015870:Gene Expression; D005838:Genotype; D006801:Humans; D007150:Immunohistochemistry; D007194:India; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D008969:Molecular Sequence Data; D009367:Neoplasm Staging; D017354:Point Mutation; D012189:Retrospective Studies; D017384:Sequence Deletion; D016019:Survival Analysis; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000473:pathology
chemical_list: C512478:EGFR protein, human; D066246:ErbB Receptors